SonoSite launches 180 system
Hand-held ultrasound manufacturer SonoSite has begun shipping its SonoSite 180 ultrasound system worldwide. SonoSite received the CE Mark Sept. 15 for the system. The certification gives the Bothell, WA, company rights to distribute the system throughout
Hand-held ultrasound manufacturer SonoSite has begun shipping its SonoSite 180 ultrasound system worldwide. SonoSite received the CE Mark Sept. 15 for the system. The certification gives the Bothell, WA, company rights to distribute the system throughout the European Union.
The 5-lb unit allows for color power Doppler capability and uses digital broadband beam-forming technology. SonoSite received 510(k) clearance from the Food and Drug Administration for SonoSite 180 in April (SCAN 4/28/99) for such indications as gynecology, obstetrics, and abdominal imaging. The system is configured to offer both transabdominal and intravaginal imaging, according to SonoSite.
In other SonoSite news, the company has joined Office of the Future, a research and development consortium that is working to create a clinical office model that integrates technology, information, and design. The group plans to use SonoSite 180 in the exam and procedure rooms it is developing. Office of the Future includes such companies as Midmark, American Express Healthcare Finance, American Medical Development, GE Marquette Medical Systems, Health Care Data Systems, Hewlett-Packard, Lunar, and Sony Electronics Medical Systems.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
